Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity

IF 2.7 3区医学 Q1 SURGERY American journal of surgery Pub Date : 2025-02-08 DOI:10.1016/j.amjsurg.2025.116242

Soban Maan , Amir H. Sohail , Samia Aziz Sulaiman , Linta Mansoor , Ethan M. Cohen , Ayowumi A. Adekolu , Salim Abunnaja , Nova Szoka , Lawrence E. Tabone , Shyam Thakkar , Shailendra Singh

{"title":"Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity","authors":"Soban Maan , Amir H. Sohail , Samia Aziz Sulaiman , Linta Mansoor , Ethan M. Cohen , Ayowumi A. Adekolu , Salim Abunnaja , Nova Szoka , Lawrence E. Tabone , Shyam Thakkar , Shailendra Singh","doi":"10.1016/j.amjsurg.2025.116242","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study compared cardiovascular outcomes associated with metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with obesity.</div></div><div><h3>Methods</h3><div>The TriNetX network was used to compare cardiovascular risk in adult patients with BMI ≥35 who underwent MBS with those who received GLP-1 RA therapy for ≥2 years. Primary outcome was cardiovascular disease (CVD), a composite of incident heart failure (HF), coronary artery disease (CAD), and cerebrovascular disease. Patient follow-up lasted up to 10 years.</div></div><div><h3>Results</h3><div>MBS was associated with lower hazard of the primary composite outcome of CVD (HR, 0.54, 95 % CI, 0.49–0.60), and the secondary outcomes of incident HF (HR, 0.45, 95 % CI, 0.39–0.52), CAD (HR, 0.54, 95 % CI, 0.45–0.66), and cerebrovascular disease (HR, 0.64, 95 % CI, 0.53–0.77).</div></div><div><h3>Conclusions</h3><div>A lower risk of adverse cardiovascular outcomes was noted after MBS compared with GLP-1 RA therapy in patients with obesity.</div></div>","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":"242 ","pages":"Article 116242"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002961025000649","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This study compared cardiovascular outcomes associated with metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with obesity.

Methods

The TriNetX network was used to compare cardiovascular risk in adult patients with BMI ≥35 who underwent MBS with those who received GLP-1 RA therapy for ≥2 years. Primary outcome was cardiovascular disease (CVD), a composite of incident heart failure (HF), coronary artery disease (CAD), and cerebrovascular disease. Patient follow-up lasted up to 10 years.

Results

MBS was associated with lower hazard of the primary composite outcome of CVD (HR, 0.54, 95 % CI, 0.49–0.60), and the secondary outcomes of incident HF (HR, 0.45, 95 % CI, 0.39–0.52), CAD (HR, 0.54, 95 % CI, 0.45–0.66), and cerebrovascular disease (HR, 0.64, 95 % CI, 0.53–0.77).

Conclusions

A lower risk of adverse cardiovascular outcomes was noted after MBS compared with GLP-1 RA therapy in patients with obesity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.